Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19

Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety.Objectives: Our study aims to evaluate the minimum plasma c...

Full description

Bibliographic Details
Main Authors: Jiayue Lu, Hong Cai, Yujun Hao, Zhang Lin, Shang Liu, Yaping Zhan, Li Ding, Meilan Huang, Zhenyuan Li, Lan Xu, Xiujuan Yan, Li Yang, He Zhang, Wei Zhang, Li Zhao, Junli Zhao, Ting Wang, Leyi Gu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Pharmacology
Subjects:
hemodialysis
nirmatrelvir
ritonavir
pharmacokinetics
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1161897/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1161897/full

Similar Items